Immunogenicity and safety of 'Comvigen', a bivalent SARS-CoV-2 vaccine, in comparison to Comirnaty bivalent vaccine in Thailand: a phase 2, non-inferiority randomised trial
在泰国开展的一项 II 期非劣效性随机试验，比较了二价 SARS-CoV-2 疫苗“Comvigen”与二价疫苗“Comirnaty”的免疫原性和安全性。
期刊:Lancet Regional Health - Southeast Asia
影响因子:6.2
doi:10.1016/j.lansea.2025.100650
Jantarabenjakul, Watsamon; Nantanee, Rapisa; Puthanakit, Thanyawee; Gatechompol, Sivaporn; Avihingsanon, Anchalee; Punrin, Suda; Tantawichien, Terapong; Nitayaphan, Sorachai; Thitithanyanont, Arunee; Buranapraditkun, Supranee; Jongkaewwattana, Anan; Ketloy, Chutitorn; Prompetchara, Eakachai; Lawpoolsri, Saranath; Wijagkanalan, Wassana; Alameh, Mohamad-Gabriel; Hong, Lina; Samija, Mijo; Weissman, Drew; Ruxrungtham, Kiat
